IDEXX Laboratories, Inc. $IDXX Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 66.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,773 shares of the company’s stock after purchasing an additional 30,528 shares during the period. Natixis Advisors LLC’s holdings in IDEXX Laboratories were worth $51,939,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Beacon Investment Advisory Services Inc. boosted its holdings in shares of IDEXX Laboratories by 11.9% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after buying an additional 6,710 shares during the period. Nordea Investment Management AB boosted its holdings in shares of IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after buying an additional 8,845 shares during the period. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth about $1,966,000. NEOS Investment Management LLC boosted its holdings in shares of IDEXX Laboratories by 82.7% in the third quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock worth $19,199,000 after buying an additional 13,599 shares during the period. Finally, Diversified Trust Co. boosted its holdings in shares of IDEXX Laboratories by 223.5% in the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after buying an additional 2,901 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $560.73 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The firm has a market cap of $44.23 billion, a PE ratio of 41.29, a PEG ratio of 3.20 and a beta of 1.55. The firm’s 50 day moving average price is $563.43 and its 200 day moving average price is $633.51. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on IDXX shares. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Citigroup started coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.